Clinical trials
Early Stage Breast Carcinoma clinical trials
Below are recruiting early stage breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT07263451Recruiting
Testing a new treatment for small, early breast cancers
This study tests if a new treatment called IRE (irreversible electroporation) can safely treat small, early-stage breast cancers. It's for people with a single, small tumor that has not been treated yet.
Hangzhou, ZhejiangAges 18 years+ - NCT04517266Recruiting
Testing less radiation to the inner breast area
This trial studies whether some patients with early-stage breast cancer can safely skip a specific part of radiation to the inner chest (called internal mammary irradiation). It may reduce radiation side effects while still aiming to prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07054190RecruitingPhase 2
Testing Inavolisib in early-stage breast cancer with PIK3CA mutation
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
Los Angeles, CaliforniaAges 18 years+ - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07539038Recruiting
Exercise Program for Early-Stage Hormone-Positive Breast Cancer
This study tests whether a structured exercise program helps women with early-stage hormone-positive breast cancer who are taking endocrine therapy (hormone-blocking medications). The goal is to see if physical activity improves outcomes and quality of life during treatment.
Aviano, PordenoneAges 18 years+ - NCT03936478RecruitingPhase 2
MRI-guided partial breast radiation in three short treatments
This study tests a faster, targeted type of radiation for early breast cancer, using real-time MRI to help plan and guide treatment. It may help deliver the same cancer-fighting effect while limiting radiation to the rest of the breast.
Madison, WisconsinAges 40 years+ - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT04427293RecruitingPhase 1
Testing lenvatinib and pembrolizumab before breast cancer surgery
This early-phase trial tests whether lenvatinib plus pembrolizumab given before surgery can help treat early-stage triple-negative breast cancer. If you qualify, you would receive study medicines before your planned operation to remove the tumor and nearby lymph nodes.
Chicago, IllinoisAges 18 years+ - NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Jonesboro, ArkansasAges 18 years+ - NCT07106632RecruitingPhase 3
Genomic test to guide chemotherapy in young women with breast cancer
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
BrusselsAges 35–45 - NCT06375798Recruiting
Breast conservation with radiation during surgery for early breast cancer
This trial is for women aged 55 or older with very early-stage breast cancer (stage 0 or 1) who want to save their breast. It tests giving a single dose of radiation during the lumpectomy instead of weeks of daily radiation afterward.
Shijiazhuang, HebeiAges 55 years+ - NCT06102863RecruitingPhase 2
Progesterone and statins for young women with early endometrial cancer or atypical hyperplasia
This trial tests whether adding a statin to progesterone therapy helps young women with early endometrial cancer or atypical endometrial hyperplasia who want to preserve their fertility. It aims to find a better treatment option for those who may not respond well to progesterone alone.
Beijing, Beijing MunicipalityAges 17–45 - NCT07507890Recruiting
Nipple-sparing mastectomy through one armpit incision
This trial tests a less invasive surgery for early-stage breast cancer that removes breast tissue through a single small cut in the armpit while keeping the nipple. It may be an option for women with small to medium breasts who are candidates for immediate breast reconstruction.
Candiolo, TurinAges 18 years+ - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT07178171RecruitingPhase 1
QL1706 + short chemo for early triple-negative breast cancer
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–70 - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT04353557Recruiting
Blood test monitoring in early-stage breast cancer
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT06535893RecruitingPhase 2
Testing new treatments for early breast cancer
This trial tests new treatments for early breast cancer (stage II or III). It aims to find better therapies that can stop the cancer from coming back, and you may receive a promising new drug.
Nagoya, Aichi-kenAges 18–80 - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT06738654Recruiting
Robot-assisted scarless breast-conserving surgery for breast cancer
This trial uses a robotic arm through the armpit to remove breast cancer while leaving no visible scar on the chest. It is for women with early-stage breast cancer who want to keep their breast and avoid a scar.
Chongqing, Chongqing MunicipalityAges 18–65
Hear when a new Early Stage Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early stage breast carcinoma?
- Yes. Clin2 currently lists 147 recruiting early stage breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early stage breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early stage breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.